TY  - JOUR
AU  - Rosenheck, Justin P.
AU  - Botros, Mena M
AU  - Nunley, David N
PY  - 2021
DA  - 2021/06/27
TI  - Cytomegalovirus in Lung Transplant
JO  - OBM Transplantation
SP  - 145
VL  - 05
IS  - 02
AB  - Lung transplantation is a therapeutic option for patients with advanced lung diseases. Lung transplant outcomes have improved over time with improvements in the management of these complex patients. Cytomegalovirus is a common opportunistic organism affecting all solid organ transplant recipients. Characteristics unique to lung transplantation can make this virus difficult to manage, with myriad complications including graft failure and death. Ongoing research into and understanding of cytomegalovirus has opened exciting new avenues of management. We discuss the various manifestations of CMV related pathologies in the lung transplant recipient. We discuss current mainstays of risk stratification, diagnosis, and treatment, as well as present new and evolving concepts. Current medications are highly effective at preventing and treating CMV manifestations, but may be poorly tolerated. A new generation of therapies carry the promise of efficacy, with a greater safety profile and improved tolerance of adverse effects. We discuss host-virus immune interactions, specifically how these can be utilized in clinical practice to individualize the cytomegalovirus related care of lung transplant recipients. Finally, we turn our attention to the near horizon as we continue to evolve the care of this unique population.
SN  - 2577-5820
UR  - https://doi.org/10.21926/obm.transplant.2102145
DO  - 10.21926/obm.transplant.2102145
ID  - Rosenheck2021
ER  -